TY - JOUR
T1 - Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease
AU - Flores, Shaney
AU - Chen, Charles D.
AU - Su, Yi
AU - Dincer, Aylin
AU - Keefe, Sarah J.
AU - McKay, Nicole S.
AU - Paulick, Angela M.
AU - Perez-Carrillo, Gloria Guzman
AU - Wang, Liang
AU - Hornbeck, Russ C.
AU - Goyal, Manu
AU - Vlassenko, Andrei
AU - Schwarz, Sally
AU - Nickels, Michael L.
AU - Wong, Dean F.
AU - Tu, Zhude
AU - McConathy, Jonathan E.
AU - Morris, John C.
AU - Benzinger, Tammie L.S.
AU - Gordon, Brian A.
N1 - Funding Information:
This research was supported by NIH grants: P30AG66444, P01AG003991,
Funding Information:
This research was supported by NIH grants: P30AG66444, P01AG003991, P01AG026276, U01AG042791, R01AG046179, R01AG055444, and R01AG031581. Image acquisition and analysis received additional support from UL1TR000448, P30NS098577, and R01EB009352. Additional support provided by Arizona Alzheimer's Research Consortium, the Charles and Joanne Knight Alzheimer Disease Research Center Support Fund, the David and Betty Farrell Medical Research Fund, the Daniel J. Brennan Alzheimer Research Fund, the Fred Simmons and Olga Mohan Alzheimer Research Support Fund, the Barnes-Jewish Hospital Foundation, Eli Lilly & Co., Hoffman La-Roche, Avid Radiopharmaceuticals, Alzheimer's Association, GHR Foundation, and an anonymous organization. Avid Radiopharmaceuticals provided the FBP doses and assisted with scanning expenses, as well as provided precursor and technology transfer for FTP.
Funding Information:
reports investigator-initiated funding from the National Institutes of Health (NIH) and contracts to
Funding Information:
reports investigator-initiated funding from the NIH, the Alzheimer’s Association, Barnes-Jewish
Publisher Copyright:
© 2023 Society of Nuclear Medicine Inc.. All rights reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Rationale: Off-target binding of [18F]flortaucipir (FTP) can complicate quantitative positron emission tomography (PET) analyses. An underdiscussed off-target region is the skull. Here we characterize how often FTP skull binding occurs, its influence on estimates of Alzheimer disease (AD) pathology, its potential drivers, and whether skull uptake is a stable feature across time and tracers. Methods: In 313 cognitively normal and mildly impaired participants, computerized tomography (CT) scans were used to define a skull mask. This mask was used to quantify FTP skull uptake. Skull uptake of amyloid-beta PET tracers [18F]florbetapir and [11C]Pittsburgh Compound B (PiB; n=152) were also assessed. Gaussian mixture modeling defined abnormal levels of skull binding for each tracer. We examined the relationship of continuous bone uptake to known off-target binding in the basal ganglia and choroid plexus as well as skull density measured from the CT. Finally, we examined the confounding effect of skull binding on pathological quantification. Results: We found 50/313 (~16%) FTP scans had high levels of skull signal. The majority were female (n=41, 82%) and, in women, lower skull density was related to higher FTP skull signal. Visual reads by a neuroradiologist revealed a significant relationship with hyperostosis; however, only 21% of women with high skull binding were diagnosed with hyperostosis. FTP skull signal did not substantially correlate with other known off-target regions. Skull uptake was consistent over longitudinal FTP scans and across tracers. In amyloid-beta negative, but not positive, individuals, FTP skull binding impacted quantitative estimates in temporal regions. Conclusion: FTP skull binding is a stable, participant-specific phenomenon and is unrelated to known off-target regions. Effects were primarily found in women, and partially related to lower bone density. Presence of PiB skull binding suggests defluorination does not fully explain FTP skull signal. As signal in skull bone can impact quantitative analyses and differs across sex, it should be explicitly addressed in studies of aging and AD.
AB - Rationale: Off-target binding of [18F]flortaucipir (FTP) can complicate quantitative positron emission tomography (PET) analyses. An underdiscussed off-target region is the skull. Here we characterize how often FTP skull binding occurs, its influence on estimates of Alzheimer disease (AD) pathology, its potential drivers, and whether skull uptake is a stable feature across time and tracers. Methods: In 313 cognitively normal and mildly impaired participants, computerized tomography (CT) scans were used to define a skull mask. This mask was used to quantify FTP skull uptake. Skull uptake of amyloid-beta PET tracers [18F]florbetapir and [11C]Pittsburgh Compound B (PiB; n=152) were also assessed. Gaussian mixture modeling defined abnormal levels of skull binding for each tracer. We examined the relationship of continuous bone uptake to known off-target binding in the basal ganglia and choroid plexus as well as skull density measured from the CT. Finally, we examined the confounding effect of skull binding on pathological quantification. Results: We found 50/313 (~16%) FTP scans had high levels of skull signal. The majority were female (n=41, 82%) and, in women, lower skull density was related to higher FTP skull signal. Visual reads by a neuroradiologist revealed a significant relationship with hyperostosis; however, only 21% of women with high skull binding were diagnosed with hyperostosis. FTP skull signal did not substantially correlate with other known off-target regions. Skull uptake was consistent over longitudinal FTP scans and across tracers. In amyloid-beta negative, but not positive, individuals, FTP skull binding impacted quantitative estimates in temporal regions. Conclusion: FTP skull binding is a stable, participant-specific phenomenon and is unrelated to known off-target regions. Effects were primarily found in women, and partially related to lower bone density. Presence of PiB skull binding suggests defluorination does not fully explain FTP skull signal. As signal in skull bone can impact quantitative analyses and differs across sex, it should be explicitly addressed in studies of aging and AD.
KW - amyloid PET
KW - human
KW - off-target binding
KW - tau PET
UR - http://www.scopus.com/inward/record.url?scp=85147318265&partnerID=8YFLogxK
U2 - 10.2967/jnumed.122.263948
DO - 10.2967/jnumed.122.263948
M3 - Article
C2 - 35953305
AN - SCOPUS:85147318265
SN - 0161-5505
VL - 64
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 2
ER -